Respiratory virus surveillance varies widely between nursing homes (NHs) and is shaped by differences in staffing capacity, provider training, diagnostic resources, and facility-level protocols. CLIA-waived, point-of-care molecular testing devices were implemented as routine respiratory virus surveillance in 23 Medicare-certified U.S. NHs to evaluate feasibility.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: